The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition and methods for inhibiting the expression of the huntingtin gene in a cell.
